{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 29,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/14",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.904,
        "x": 0.048,
        "y": 0.21
      },
      "kind": "list",
      "text": "Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients. ~15,000 new cases per year in the U.S. alone. WHO, CDC, and FDA consider IA a critical priority and a global public health concern.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bb504ad-9e95-4683-bc89-37406e369d39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.904,
        "x": 0.048,
        "y": 0.69
      },
      "kind": "list",
      "text": "Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only). Rare disease/orphan commercial opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd24fd5d-0841-40e8-aa01-11a49419c37e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.904,
        "x": 0.048,
        "y": 0.405
      },
      "kind": "list",
      "text": "IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks. Azole use requires significant expertise to manage toxicities and significant drug-drug interactions that often limits duration of use. Resistance to azoles has been increasing globally. Recently, cases of breakthrough IA have been reported in patients receiving antifungal prophylaxis. Failures attributed to non-compliance, poor absorption, DDIs, or infection with a drug-resistant Aspergillus species.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc660f15-3dbd-4cca-bf1c-8d1dd0336029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.486,
        "x": 0.257,
        "y": 0.875
      },
      "kind": "source-note",
      "text": "* Phase 3 trial dependent on securing partnership(s) or non-dilutive government funds",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "101375b3-2582-4834-9531-a2a61dc0bea2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.765,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc511ed1-9225-4230-8211-768985e5a51f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "af59028c-0eed-4467-850e-1335ed528ac8",
      "evidence": "High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fd41420c-fa22-4dd2-95bb-fdbd4acdd6cb",
      "evidence": "Slides 7-14 highlight the growing threat of IFIs and the limitations of current treatments.",
      "position": 0,
      "objective": "What is the cost of not addressing IFIs effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}